bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 11 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Supplementary Figure
Figure S2 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors: Ji Jennifer X. , Cochrane Dawn R. , Tessier-Cloutier Basile , Chen Shary Yutin , Ho Germain , Pathak Khyatiben V. , Alcazar Isabel N. , Farnell David , Leung Samuel , Cheng Angela , Chow Christine , Colborne Shane , Negri Gian Luca , Kommoss Friedrich , Karnezis Anthony , Morin Gregg B. , McAlpine Jessica N. , Gilks C. Blake , Weissman Bernard E. , Trent Jeffrey M. , Hoang Lynn , Pirrotte Patrick , Wang Yemin , Huntsman David G.
Published: April 2023

ASS1 expression does not correlate with survival in CCOC and ENOC. Kaplan-Meier plots with risk table comparing intense ASS1 expression (histoscore = 300, red line) to low/moderate ASS1 expression (histoscore <300, black line) for A, overall survival in CCOC; B, progression free survival in CCOC; C, overall survival in ENOC; and D, progression-free survival in ENOC.
Supplementary Figure 10 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Supplementary Figure
Supplementary Figure 1 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Supplementary Figure
Supplementary Data from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Clinical trial protocol
Supplementary Appendix from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

supplementary appendix
Supplementary Data from Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Authors: Marsavela Gabriela , Lee Jenny , Calapre Leslie , Wong Stephen Q. , Pereira Michelle R. , McEvoy Ashleigh C. , Reid Anna L. , Robinson Cleo , Warburton Lydia , Abed Afaf , Khattak Muhammad A. , Meniawy Tarek M. , Dawson Sarah-Jane , Sandhu Shahneen , Carlino Matteo S. , Menzies Alexander M. , Scolyer Richard A. , Long Georgina V. , Amanuel Benhur , Millward Michael , Ziman Melanie R. , Rizos Helen , Gray Elin S.
Published: April 2023

Tables S1-S8 and Figures S1-S4
Supplementary Data from Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors
Authors: Subbiah Vivek , Erwin William , Mawlawi Osama , McCoy Asa , Wages David , Wheeler Catherine , Gonzalez-Lepera Carlos , Liu Holly , Macapinlac Homer , Meric-Bernstam Funda , Hong David S. , Pant Shubham , Le Dao , Santos Elmer , Gonzalez Jose , Roszik Jason , Suzuki Takeaki , Subach Ruth Ann , Madden Timothy , Johansen Mary , Nomura Fumiko , Satoh Hirokazu , Matsuura Tadashi , Kajita Masamichi , Nakamura Eri , Funase Yuichi , Matsushima Satoshi , Ravizzini Gregory
Published: April 2023

Supplemental files for "Phase 1 Study of P-cadherin-Targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors" Subbiah V et al.
Supplementary Data from Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of CTNNB1 Mutational Status
Authors: Mir Olivier , Honoré Charles , Chamseddine Ali N. , Dômont Julien , Dumont Sarah N. , Cavalcanti Andrea , Faron Matthieu , Rimareix Françoise , Haddag-Miliani Leila , Le Péchoux Cécile , Levy Antonin , Court Charles , Briand Sylvain , Fadel Elie , Mercier Olaf , Bayle Arnaud , Brunet Anaïs , Ngo Carine , Rouleau Etienne , Adam Julien , Le Cesne Axel
Published: April 2023

Supplementary tables 1-3 and supplementary figures 1-3
Supplementary Data 6 from Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma
Authors: Bachet Jean-Baptiste , Blons Hélène , Hammel Pascal , Hariry Iman El , Portales Fabienne , Mineur Laurent , Metges Jean-Philippe , Mulot Claire , Bourreau Camille , Cain Jason , Cros Jérôme , Laurent-Puig Pierre
Published: April 2023

Evolution of the maximal variant allelic fraction during the first three cycles in the 40 patients with all three available points.
Video S2 from Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
Authors: Fraunhoffer Nicolas A. , Abuelafia Analía Meilerman , Bigonnet Martin , Gayet Odile , Roques Julie , Telle Emmanuel , Santofimia-Castaño Patricia , Borrello María Teresa , Chuluyan Eduardo , Dusetti Nelson , Iovanna Juan
Published: April 2023

Supplementary Video S2
Video S1 from Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
Authors: Fraunhoffer Nicolas A. , Abuelafia Analía Meilerman , Bigonnet Martin , Gayet Odile , Roques Julie , Telle Emmanuel , Santofimia-Castaño Patricia , Borrello María Teresa , Chuluyan Eduardo , Dusetti Nelson , Iovanna Juan
Published: April 2023

Supplementary Video S1
Supplementary Data 2 from Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma
Authors: Bachet Jean-Baptiste , Blons Hélène , Hammel Pascal , Hariry Iman El , Portales Fabienne , Mineur Laurent , Metges Jean-Philippe , Mulot Claire , Bourreau Camille , Cain Jason , Cros Jérôme , Laurent-Puig Pierre
Published: April 2023

Figure S2a: Overall survival of patients with or without at least one available plasma sample. Figure S2b: Overall survival curves according to treatment arms for the 122 patients with at least one available plasma sample. Figure S2c: Progression free survival curves according to treatment arms for the 122 patients with at least one available plasma sample.
Supplementary Figure S3 from Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
Authors: Fraunhoffer Nicolas A. , Abuelafia Analía Meilerman , Bigonnet Martin , Gayet Odile , Roques Julie , Telle Emmanuel , Santofimia-Castaño Patricia , Borrello María Teresa , Chuluyan Eduardo , Dusetti Nelson , Iovanna Juan
Published: April 2023

Supplementary Figure S3
Supplementary Data from Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment
Authors: Chen Runzhe , Lee Won-Chul , Fujimoto Junya , Li Jun , Hu Xin , Mehran Reza , Rice David , Swisher Stephen G. , Sepesi Boris , Tran Hai T. , Chow Chi-Wan , Little Latasha D. , Gumbs Curtis , Haymaker Cara , Heymach John V. , Wistuba Ignacio I. , Lee J. Jack , Futreal P. Andrew , Zhang Jianhua , Reuben Alexandre , Tsao Anne S. , Zhang Jianjun
Published: April 2023

Mutation list
Legend of Supplementary Data from Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
Authors: Fraunhoffer Nicolas A. , Abuelafia Analía Meilerman , Bigonnet Martin , Gayet Odile , Roques Julie , Telle Emmanuel , Santofimia-Castaño Patricia , Borrello María Teresa , Chuluyan Eduardo , Dusetti Nelson , Iovanna Juan
Published: April 2023

Legend of Supplementary Data
Supplementary Table 4 from A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Authors: Pishvaian Michael J. , Wang Hongkun , He Aiwu Ruth , Hwang Jimmy J. , Smaglo Brandon G. , Kim Sunnie S. , Weinberg Benjamin A. , Weiner Louis M. , Marshall John L. , Brody Jonathan R.
Published: April 2023

Details of the Patients with HR-DDR Mutations.
Table S3 from TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Authors: Rosen Ezra Y. , Goldman Debra A. , Hechtman Jaclyn F. , Benayed Ryma , Schram Alison M. , Cocco Emiliano , Shifman Sophie , Gong Yixiao , Kundra Ritika , Solomon James P. , Bardelli Alberto , Scaltriti Maurizio , Drilon Alexander , Iasonos Alexia , Taylor Barry S. , Hyman David M.
Published: April 2023

Supplemental Table 3. Detail of patients who received chemotherapy by cancer type.
Supplementary Table 2 from A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Authors: Pishvaian Michael J. , Wang Hongkun , He Aiwu Ruth , Hwang Jimmy J. , Smaglo Brandon G. , Kim Sunnie S. , Weinberg Benjamin A. , Weiner Louis M. , Marshall John L. , Brody Jonathan R.
Published: April 2023

Veliparib pharmacokinetics
Table S2 from TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Authors: Rosen Ezra Y. , Goldman Debra A. , Hechtman Jaclyn F. , Benayed Ryma , Schram Alison M. , Cocco Emiliano , Shifman Sophie , Gong Yixiao , Kundra Ritika , Solomon James P. , Bardelli Alberto , Scaltriti Maurizio , Drilon Alexander , Iasonos Alexia , Taylor Barry S. , Hyman David M.
Published: April 2023

Supplemental Table 2. Most commonly mutated genes in the TRK cohort.
Supplementary Table 1 from A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Authors: Pishvaian Michael J. , Wang Hongkun , He Aiwu Ruth , Hwang Jimmy J. , Smaglo Brandon G. , Kim Sunnie S. , Weinberg Benjamin A. , Weiner Louis M. , Marshall John L. , Brody Jonathan R.
Published: April 2023

Veliparib dose levels
Table S1 from TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Authors: Rosen Ezra Y. , Goldman Debra A. , Hechtman Jaclyn F. , Benayed Ryma , Schram Alison M. , Cocco Emiliano , Shifman Sophie , Gong Yixiao , Kundra Ritika , Solomon James P. , Bardelli Alberto , Scaltriti Maurizio , Drilon Alexander , Iasonos Alexia , Taylor Barry S. , Hyman David M.
Published: April 2023

Supplemental Table 1. NTRK gene fusion partners.
Supplementary Materials from A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Authors: Pishvaian Michael J. , Wang Hongkun , He Aiwu Ruth , Hwang Jimmy J. , Smaglo Brandon G. , Kim Sunnie S. , Weinberg Benjamin A. , Weiner Louis M. , Marshall John L. , Brody Jonathan R.
Published: April 2023

Written Description of the Supplementary Methods; and the Supplementary Figure/Table Legends
Supplementary Figure 1 from A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Authors: Pishvaian Michael J. , Wang Hongkun , He Aiwu Ruth , Hwang Jimmy J. , Smaglo Brandon G. , Kim Sunnie S. , Weinberg Benjamin A. , Weiner Louis M. , Marshall John L. , Brody Jonathan R.
Published: April 2023

Visual Depiction of the therapy dosing, and pharmacokinetic (PK) sampling schedule for patients in the Phase I portion of the trial.
Table S2 from Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer
Authors: Cooper Alissa J. , Kobayashi Yoshihisa , Kim Dewey , Clifford Sarah E. , Kravets Sasha , Dahlberg Suzanne E. , Chambers Emily S. , Li Jiaqi , Rangachari Deepa , Nguyen Tom , Costa Daniel B. , Rabin Michael S. , Wagle Nikhil , Sholl Lynette M. , Jänne Pasi A , Oxnard Geoffrey R.
Published: April 2023

Demographics of study participants.
Supplementary Fig. S4 from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Authors: Tanimoto Azusa , Matsumoto Shingo , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Nishiyama Akihiro , Yoh Kiyotaka , Ikeda Takaya , Furuya Naoki , Nishino Kazumi , Ohe Yuichiro , Goto Koichi , Yano Seiji
Published: April 2023

Kaplan-Meier curves for PFS according to ATM mutation status in patients who received alectinib (A) or either of ALK-TKIs (alectinib, crizotinib, brigatinib, lorlatinib, ceritinib) (B) as the first TKI treatment.
Supplementary Fig. S2 from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Authors: Tanimoto Azusa , Matsumoto Shingo , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Nishiyama Akihiro , Yoh Kiyotaka , Ikeda Takaya , Furuya Naoki , Nishino Kazumi , Ohe Yuichiro , Goto Koichi , Yano Seiji
Published: April 2023

Kaplan-Meier curves for PFS according to TP53 mutation status in patients who received either of ALK-TKIs (alectinib, crizotinib, brigatinib, lorlatinib, ceritinib) as the first TKI treatment.
Table S3 from Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma
Authors: Spassova Ivelina , Ugurel Selma , Terheyden Patrick , Sucker Antje , Hassel Jessica C. , Ritter Cathrin , Kubat Linda , Habermann Daniel , Farahpour Farnoush , Saeedghalati Mohammadkarim , Peiffer Lukas , Kumar Rajiv , Schrama David , Hoffmann Daniel , Schadendorf Dirk , Becker Jürgen C.
Published: April 2023

Supplementary Table S3. Differentially expressed genes between responders and non-responders
Table S1 from Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma
Authors: Spassova Ivelina , Ugurel Selma , Terheyden Patrick , Sucker Antje , Hassel Jessica C. , Ritter Cathrin , Kubat Linda , Habermann Daniel , Farahpour Farnoush , Saeedghalati Mohammadkarim , Peiffer Lukas , Kumar Rajiv , Schrama David , Hoffmann Daniel , Schadendorf Dirk , Becker Jürgen C.
Published: April 2023

Supplementary Table S1. Antibodies and procedures used for multiplexed immunofluorescence staining
Supplementary material from Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma
Authors: Spassova Ivelina , Ugurel Selma , Terheyden Patrick , Sucker Antje , Hassel Jessica C. , Ritter Cathrin , Kubat Linda , Habermann Daniel , Farahpour Farnoush , Saeedghalati Mohammadkarim , Peiffer Lukas , Kumar Rajiv , Schrama David , Hoffmann Daniel , Schadendorf Dirk , Becker Jürgen C.
Published: April 2023

Supplementary material (Bayes Analysis)
Figure S2 from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Authors: Tannir Nizar M. , Signoretti Sabina , Choueiri Toni K. , McDermott David F. , Motzer Robert J. , Flaifel Abdallah , Pignon Jean-Christophe , Ficial Miriam , Frontera Osvaldo Arén , George Saby , Powles Thomas , Donskov Frede , Harrison Michael R. , Barthélémy Philippe , Tykodi Scott S. , Kocsis Judit , Ravaud Alain , Rodriguez-Cid Jeronimo R. , Pal Sumanta K. , Murad Andre M. , Ishii Yuko , Saggi Shruti Shally , McHenry M. Brent , Rini Brian I.
Published: April 2023

Treatment-free interval, duration of therapy, duration of response, and subsequent systemic therapy in all patients with sRCC and I/P-risk disease and confirmed response (A, complete responders; B, partial responders).
Figure S1 from Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma
Authors: Spassova Ivelina , Ugurel Selma , Terheyden Patrick , Sucker Antje , Hassel Jessica C. , Ritter Cathrin , Kubat Linda , Habermann Daniel , Farahpour Farnoush , Saeedghalati Mohammadkarim , Peiffer Lukas , Kumar Rajiv , Schrama David , Hoffmann Daniel , Schadendorf Dirk , Becker Jürgen C.
Published: April 2023

Supplementary Figure S1. CONSORT diagram of the experimental study design.
Supplementary Figure S4 from Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection
Authors: Guo Jimmy A. , Hoffman Hannah I. , Shroff Stuti G. , Chen Peter , Hwang Peter G. , Kim Daniel Y. , Kim Daniel W. , Cheng Stephanie W. , Zhao Daniel , Mahal Brandon A. , Alshalalfa Mohammed , Niemierko Andrzej , Wo Jennifer Y. , Loeffler Jay S. , Fernandez-del Castillo Carlos , Jacks Tyler , Aguirre Andrew J. , Hong Theodore S. , Mino-Kenudson Mari , Hwang William L.
Published: April 2023

Supplementary Figure S4
Table S3 from Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial
Authors: Guerini-Rocco Elena , Gray Kathryn P. , Fumagalli Caterina , Reforgiato Marta Rita , Leone Isabella , Rafaniello Raviele Paola , Munzone Elisabetta , Kammler Roswitha , Neven Patrick , Hitre Erika , Jerusalem Guy , Simoncini Edda , Gombos Andrea , Deleu Ines , Karlsson Per , Aebi Stefan , Chirgwin Jacquie , Di Lauro Vincenzo , Thompson Alastair , Graas Marie-Pascale , Barber Matthew , Fontaine Christel , Loibl Sibylle , Gavilá Joaquín , Kuroi Katsumasa , Müller Bettina , O’Reilly Seamus , Di Leo Angelo , Goldhirsch Aron , Viale Giuseppe , Barberis Massimo , Regan Meredith M. , Colleoni Marco
Published: April 2023

Distribution of focal copy number gains identified in the genes targeted for copy number gain (CNG) analysis according to tumor subtypes.
Table S2 from Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial
Authors: Guerini-Rocco Elena , Gray Kathryn P. , Fumagalli Caterina , Reforgiato Marta Rita , Leone Isabella , Rafaniello Raviele Paola , Munzone Elisabetta , Kammler Roswitha , Neven Patrick , Hitre Erika , Jerusalem Guy , Simoncini Edda , Gombos Andrea , Deleu Ines , Karlsson Per , Aebi Stefan , Chirgwin Jacquie , Di Lauro Vincenzo , Thompson Alastair , Graas Marie-Pascale , Barber Matthew , Fontaine Christel , Loibl Sibylle , Gavilá Joaquín , Kuroi Katsumasa , Müller Bettina , O’Reilly Seamus , Di Leo Angelo , Goldhirsch Aron , Viale Giuseppe , Barberis Massimo , Regan Meredith M. , Colleoni Marco
Published: April 2023

Distribution of mutations identified in the genes targeted for mutation (SNV) analysis according to tumor subtypes.
Supplementary Figure S1 from Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection
Authors: Guo Jimmy A. , Hoffman Hannah I. , Shroff Stuti G. , Chen Peter , Hwang Peter G. , Kim Daniel Y. , Kim Daniel W. , Cheng Stephanie W. , Zhao Daniel , Mahal Brandon A. , Alshalalfa Mohammed , Niemierko Andrzej , Wo Jennifer Y. , Loeffler Jay S. , Fernandez-del Castillo Carlos , Jacks Tyler , Aguirre Andrew J. , Hong Theodore S. , Mino-Kenudson Mari , Hwang William L.
Published: April 2023

Supplementary Figure S1
Supplementary Figure 3 from Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice
Authors: Zhang Ian Y. , Zhou Hui , Liu Huili , Zhang Leying , Gao Hang , Liu Shunan , Song Yanyan , Alizadeh Darya , Yin Hongwei Holly , Pillai Raju , Badie Behnam
Published: April 2023

Supplementary Figure 3
Supplementary Data - Clean from First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Authors: Falchook Gerald S. , Kurzrock Razelle , Amin Hesham M. , Xiong Wenyuan , Fu Siqing , Piha-Paul Sarina A. , Janku Filip , Eskandari Ghazaleh , Catenacci Daniel V. , Klevesath Manfred , Bruns Rolf , Stammberger Uz , Johne Andreas , Bladt Friedhelm , Friese-Hamim Manja , Girard Pascal , El Bawab Samer , Hong David S.
Published: April 2023

Supplementary information showing details of study criteria, bioasssays, preclinical modelling, PK data, safety and efficacy.
Table S1 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
Authors: Gopal Ajay K. , Levy Ronald , Houot Roch , Patel Sandip P. , Popplewell Leslie , Jacobson Caron , Mu Xinmeng J. , Deng Shibing , Ching Keith A. , Chen Ying , Davis Craig B. , Huang Bo , Fly Kolette D. , Thall Aron , Woolfson Adrian , Bartlett Nancy L.
Published: April 2023

Select laboratory abnormalities by maximum CTCAE grade
Supplementary Tables S2-S7 from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
Authors: Hellmann Matthew D. , Nabet Barzin Y. , Rizvi Hira , Chaudhuri Aadel A. , Wells Daniel K. , Dunphy Mark P.S. , Chabon Jacob J. , Liu Chih Long , Hui Angela B. , Arbour Kathryn C. , Luo Jia , Preeshagul Isabel R. , Moding Everett J. , Almanza Diego , Bonilla Rene F. , Sauter Jennifer L. , Choi Hyejin , Tenet Megan , Abu-Akeel Mohsen , Plodkowski Andrew J. , Perez Johnston Rocio , Yoo Christopher H. , Ko Ryan B. , Stehr Henning , Gojenola Linda , Wakelee Heather A. , Padda Sukhmani K. , Neal Joel W. , Chaft Jamie E. , Kris Mark G. , Rudin Charles M. , Merghoub Taha , Li Bob T. , Alizadeh Ash A. , Diehn Maximilian
Published: April 2023

Table S2: Surveillance plasma sample ctDNA metrics. Table S3: Baseline plasma sample ctDNA metrics. Table S4: Surveillance plasma sample variants in ctDNA detected samples. Table S5: Baseline plasma variants in available samples. Table S6: Tumor variants detected by whole exome and targeted sequencing. Table S7: Canonical genes implicated in clonal hematopoiesis.
Supplementary Data from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Authors: Hackeng Wenzel M. , Dreijerink Koen M.A. , de Leng Wendy W.J. , Morsink Folkert H.M. , Valk Gerlof D. , Vriens Menno R. , Offerhaus G. Johan A. , Geisenberger Christoph , Brosens Lodewijk A.A.
Published: April 2023

Figure S1-9 and Table S1
Supplementary Data 3 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Authors: Hackeng Wenzel M. , Dreijerink Koen M.A. , de Leng Wendy W.J. , Morsink Folkert H.M. , Valk Gerlof D. , Vriens Menno R. , Offerhaus G. Johan A. , Geisenberger Christoph , Brosens Lodewijk A.A.
Published: April 2023

Cohort class score descriptives
Supplemental Figure 3 from Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
Authors: Alewine Christine , Ahmad Mehwish , Peer Cody J. , Hu Zishuo I. , Lee Min-Jung , Yuno Akira , Kindrick Jessica D. , Thomas Anish , Steinberg Seth M. , Trepel Jane B. , Figg William D. , Hassan Raffit , Pastan Ira
Published: April 2023

Serious adverse events unrelated to research.
Figure S6 from Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma
Authors: Daemen Anneleen , Cooper Jonathan E. , Myrta Szymon , Wongchenko Matthew J. , Lin Eva , Long Jason E. , Foreman Oded , Modrusan Zora , Tremayne Jarrod R. , de la Cruz Cecile C. , Merchant Mark , Martin Scott E. , Yan Yibing , Junttila Melissa R.
Published: April 2023

Supplemental Figure 6. Subtype-specific response to MAPK inhibition.
Figure S5 from Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma
Authors: Daemen Anneleen , Cooper Jonathan E. , Myrta Szymon , Wongchenko Matthew J. , Lin Eva , Long Jason E. , Foreman Oded , Modrusan Zora , Tremayne Jarrod R. , de la Cruz Cecile C. , Merchant Mark , Martin Scott E. , Yan Yibing , Junttila Melissa R.
Published: April 2023

Supplemental Figure 5. Identification of subtypes across preclinical models.
Supplementary Table S1 and S2 from Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma
Authors: Wozniak Agnieszka , Boeckx Bram , Modave Elodie , Weaver Amy , Lambrechts Diether , Littlefield Bruce A. , Schöffski Patrick
Published: April 2023

Significant focal events detected in leiomyosarcoma from EISAI 309 trial
Figure S4 from Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma
Authors: Daemen Anneleen , Cooper Jonathan E. , Myrta Szymon , Wongchenko Matthew J. , Lin Eva , Long Jason E. , Foreman Oded , Modrusan Zora , Tremayne Jarrod R. , de la Cruz Cecile C. , Merchant Mark , Martin Scott E. , Yan Yibing , Junttila Melissa R.
Published: April 2023

Supplemental Figure 4. Prognostic value of STK11 status relative to transcriptional subtype.
Figure S3 from Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma
Authors: Daemen Anneleen , Cooper Jonathan E. , Myrta Szymon , Wongchenko Matthew J. , Lin Eva , Long Jason E. , Foreman Oded , Modrusan Zora , Tremayne Jarrod R. , de la Cruz Cecile C. , Merchant Mark , Martin Scott E. , Yan Yibing , Junttila Melissa R.
Published: April 2023

Supplemental Figure 3. Subtype characteristics in early/advanced LUAD.
Supplementary Materials and Methods from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo
Authors: Anastasiadou Eleni , Seto Anita G. , Beatty Xuan , Hermreck Melanie , Gilles Maud-Emmanuelle , Stroopinsky Dina , Pinter-Brown Lauren C. , Pestano Linda , Marchese Cinzia , Avigan David , Trivedi Pankaj , Escolar Diana M. , Jackson Aimee L. , Slack Frank J.
Published: April 2023

Supplementary Materials and Methods
Figure S4 from Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study
Authors: Yi Yuxi , Shen Lijun , Shi Wei , Xia Fan , Zhang Hui , Wang Yan , Zhang Jing , Wang Yaqi , Sun Xiaoyang , Zhang Zhiyuan , Zou Wei , Yang Wang , Zhang Lingyi , Zhu Ji , Goel Ajay , Ma Yanlei , Zhang Zhen
Published: April 2023

Supplementary figures showing that baseline gut microbiome correlated with therapeutic response to nCRT in LARC patients.
Supplementary Methods from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Authors: Patnaik Amita , Yap Timothy A. , Chung Hyun Cheol , de Miguel Maria J. , Bang Yung-Jue , Lin Chia-Chi , Su Wu-Chou , Italiano Antoine , Chow Kay Hoong , Szpurka Anna M. , Yu Danni , Zhao Yumin , Carlsen Michelle , Schmidt Shelly , Vangerow Burkhard , Gandhi Leena , Xu Xiaojian , Bendell Johanna
Published: April 2023

Additional study design information, detailed inclusion/exclusion criteria, efficacy endpoint definitions, and pharmacokinetics & pharmacodynamics analysis methods
Supplemental Table 2 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Authors: Patnaik Amita , Yap Timothy A. , Chung Hyun Cheol , de Miguel Maria J. , Bang Yung-Jue , Lin Chia-Chi , Su Wu-Chou , Italiano Antoine , Chow Kay Hoong , Szpurka Anna M. , Yu Danni , Zhao Yumin , Carlsen Michelle , Schmidt Shelly , Vangerow Burkhard , Gandhi Leena , Xu Xiaojian , Bendell Johanna
Published: April 2023

Treatment-related AEs in >10% of patients in any treatment arm, and all treatment-related grade {greater than or equal to}3 AEs, for each dose cohort
Figure S1 from Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study
Authors: Yi Yuxi , Shen Lijun , Shi Wei , Xia Fan , Zhang Hui , Wang Yan , Zhang Jing , Wang Yaqi , Sun Xiaoyang , Zhang Zhiyuan , Zou Wei , Yang Wang , Zhang Lingyi , Zhu Ji , Goel Ajay , Ma Yanlei , Zhang Zhen
Published: April 2023

Flow diagram of the study design and details on the establishment of response-prediction classifier.
Table S2 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
Authors: Mathur Divya , Root Adam R. , Bugaj-Gaweda Bozena , Bisulco Stephanie , Tan Xingzhi , Fang Wei , Kearney Jessica C. , Lucas Justin , Guffroy Magali , Golas Jonathan , Rohde Cynthia M. , Stevens Chad , Kamperschroer Cris , Kelleher Kerry , Lawrence-Henderson Rosemary F. , Upeslacis Erik , Yao Johnny , Narula Jatin , LaVallie Edward R. , Fernandez Diane R. , Buetow Bernard S. , Rosfjord Edward , Bloom Laird , King Lindsay E. , Tchistiakova Lioudmila , Nguyen Anhco , Sapra Puja
Published: April 2023

Table S2. Surface Plasmon Resonance binding affinities of anti-GUCY2C/anti-CD3ε bispecifics to human, mouse and cynomolgus GUCY2C
Supplemental Figure 3 from Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Authors: Patnaik Amita , Yap Timothy A. , Chung Hyun Cheol , de Miguel Maria J. , Bang Yung-Jue , Lin Chia-Chi , Su Wu-Chou , Italiano Antoine , Chow Kay Hoong , Szpurka Anna M. , Yu Danni , Zhao Yumin , Carlsen Michelle , Schmidt Shelly , Vangerow Burkhard , Gandhi Leena , Xu Xiaojian , Bendell Johanna
Published: April 2023

Swimmer plots of abemaciclib + PD-L1 inhibitor and merestinib + PD-L1 inhibitor combination cohorts
Table S1 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
Authors: Mathur Divya , Root Adam R. , Bugaj-Gaweda Bozena , Bisulco Stephanie , Tan Xingzhi , Fang Wei , Kearney Jessica C. , Lucas Justin , Guffroy Magali , Golas Jonathan , Rohde Cynthia M. , Stevens Chad , Kamperschroer Cris , Kelleher Kerry , Lawrence-Henderson Rosemary F. , Upeslacis Erik , Yao Johnny , Narula Jatin , LaVallie Edward R. , Fernandez Diane R. , Buetow Bernard S. , Rosfjord Edward , Bloom Laird , King Lindsay E. , Tchistiakova Lioudmila , Nguyen Anhco , Sapra Puja
Published: April 2023

Immunohistochemistry based H-scores for GUCY2C cell surface expression in human colorectal, gastric, esophageal and pancreatic cancer
Figure S8 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
Authors: Mathur Divya , Root Adam R. , Bugaj-Gaweda Bozena , Bisulco Stephanie , Tan Xingzhi , Fang Wei , Kearney Jessica C. , Lucas Justin , Guffroy Magali , Golas Jonathan , Rohde Cynthia M. , Stevens Chad , Kamperschroer Cris , Kelleher Kerry , Lawrence-Henderson Rosemary F. , Upeslacis Erik , Yao Johnny , Narula Jatin , LaVallie Edward R. , Fernandez Diane R. , Buetow Bernard S. , Rosfjord Edward , Bloom Laird , King Lindsay E. , Tchistiakova Lioudmila , Nguyen Anhco , Sapra Puja
Published: April 2023

Toxicity and pharmacokinetic evaluation with PF-07062119 in cynomolgus monkeys
Supplementary Data from Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
Authors: Recondo Gonzalo , Bahcall Magda , Spurr Liam F. , Che Jianwei , Ricciuti Biagio , Leonardi Giulia C. , Lo Ying-Chun , Li Yvonne Y. , Lamberti Giuseppe , Nguyen Tom , Milan Marina S.D. , Venkatraman Deepti , Umeton Renato , Paweletz Cloud P. , Albayrak Adem , Cherniack Andrew D. , Price Kristin S. , Fairclough Stephen R. , Nishino Mizuki , Sholl Lynette M. , Oxnard Geoffrey R. , Jänne Pasi A. , Awad Mark M.
Published: April 2023

Supplementary Tables
Figure S4 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
Authors: Mathur Divya , Root Adam R. , Bugaj-Gaweda Bozena , Bisulco Stephanie , Tan Xingzhi , Fang Wei , Kearney Jessica C. , Lucas Justin , Guffroy Magali , Golas Jonathan , Rohde Cynthia M. , Stevens Chad , Kamperschroer Cris , Kelleher Kerry , Lawrence-Henderson Rosemary F. , Upeslacis Erik , Yao Johnny , Narula Jatin , LaVallie Edward R. , Fernandez Diane R. , Buetow Bernard S. , Rosfjord Edward , Bloom Laird , King Lindsay E. , Tchistiakova Lioudmila , Nguyen Anhco , Sapra Puja
Published: April 2023

cGMP assay to test GUCY2C pathway agonism and neutralization
Table S3 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Authors: Foltz Jennifer A. , Hess Brian T. , Bachanova Veronika , Bartlett Nancy L. , Berrien-Elliott Melissa M. , McClain Ethan , Becker-Hapak Michelle , Foster Mark , Schappe Timothy , Kahl Brad , Mehta-Shah Neha , Cashen Amanda F. , Marin Nancy D. , McDaniels Kristen , Moreno Chaz , Mosior Matthew , Gao Feng , Griffith Obi L. , Griffith Malachi , Wagner Julia A. , Epperla Narendranath , Rock Amy D. , Lee John , Petti Allegra A. , Soon-Shiong Patrick , Fehniger Todd A.
Published: April 2023

Summary of AntiDrug Antibody Data Incidence by Route of Administration
Figure S4 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Authors: Foltz Jennifer A. , Hess Brian T. , Bachanova Veronika , Bartlett Nancy L. , Berrien-Elliott Melissa M. , McClain Ethan , Becker-Hapak Michelle , Foster Mark , Schappe Timothy , Kahl Brad , Mehta-Shah Neha , Cashen Amanda F. , Marin Nancy D. , McDaniels Kristen , Moreno Chaz , Mosior Matthew , Gao Feng , Griffith Obi L. , Griffith Malachi , Wagner Julia A. , Epperla Narendranath , Rock Amy D. , Lee John , Petti Allegra A. , Soon-Shiong Patrick , Fehniger Todd A.
Published: April 2023

CITE-seq identifies differential modulation of PBMC subsets
Table S1 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)
Authors: Ai Xinghao , Cui Jiuwei , Zhang Jiexia , Chen Rongrong , Lin Wen , Xie Congying , Liu Anwen , Zhang Junping , Yang Weihua , Hu Xiaohua , Zhao Qiong , Rao Chuangzhou , Zang Yuan-Sheng , Ning Ruiling , Li Pansong , Chang Lianpeng , Yi Xin , Lu Shun
Published: April 2023

Gene list of the 1021 panel used in both tissue and ctDNA analysis
Figure S4 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)
Authors: Ai Xinghao , Cui Jiuwei , Zhang Jiexia , Chen Rongrong , Lin Wen , Xie Congying , Liu Anwen , Zhang Junping , Yang Weihua , Hu Xiaohua , Zhao Qiong , Rao Chuangzhou , Zang Yuan-Sheng , Ning Ruiling , Li Pansong , Chang Lianpeng , Yi Xin , Lu Shun
Published: April 2023

Kaplan-Meier curves for progression-free survival (A) Progression-free survival according to TP53 in another cluster in EGFR dominant samples defined by both tissue and ctDNA (n=51). (B) Progression-free survival according to TP53 clonal dominance status in tissue (n=100). (C) Progression-free survival according to TP53 clonal dominance status in ctDNA (n=112). (D) Progression-free survival of TP53 clonal dominance consistant in tissue and ctDNA (n=63).
Figure S2 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)
Authors: Ai Xinghao , Cui Jiuwei , Zhang Jiexia , Chen Rongrong , Lin Wen , Xie Congying , Liu Anwen , Zhang Junping , Yang Weihua , Hu Xiaohua , Zhao Qiong , Rao Chuangzhou , Zang Yuan-Sheng , Ning Ruiling , Li Pansong , Chang Lianpeng , Yi Xin , Lu Shun
Published: April 2023

Kaplan-Meier curves for progression-free survival (A) Progression-free survival according to EGFR clonal dominance status in tissue (n=100). (B) Progression-free survival of EGFR clonal dominance consistant or inconsistant patients (n=73). (C) Progression-free survival according to EGFR mutations (n=107), uncommon EGFR mutation (n=5) not analyzed. (D) Progression-free survival according to EGFR detected in ctDNA, tissue or both (n=112)
Supplementary File 3: Dose Limiting Toxicity. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
Authors: de Haan Rosemarie , van den Heuvel Michel M. , van Diessen Judi , Peulen Heike M.U. , van Werkhoven Erik , de Langen Adrianus J. , Lalezari Ferry , Pluim Dick , Verwijs-Janssen Manon , Vens Conchita , Schellens Jan H.M. , Steeghs Neeltje , Verheij Marcel , van Triest Baukelien
Published: April 2023

This file contains details on DLT (I) and DLT probabilities according to TITE-CRM in the CCRT arm (II) and (SC)RT study arm (III).
Figure S1 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)
Authors: Ai Xinghao , Cui Jiuwei , Zhang Jiexia , Chen Rongrong , Lin Wen , Xie Congying , Liu Anwen , Zhang Junping , Yang Weihua , Hu Xiaohua , Zhao Qiong , Rao Chuangzhou , Zang Yuan-Sheng , Ning Ruiling , Li Pansong , Chang Lianpeng , Yi Xin , Lu Shun
Published: April 2023

Kaplan-Meier curves for progression-free survival (A) EGFR detected in ctDNA/tissue of the 112 patients for EGFR-TKI efficacy analysis. (B) EGFR dominance analysis according to ctDNA or tissue of patients in (A). (C) Discordance of EGFR dominance analyzed by ctDNA or tissue of the 73 patients with EGFR detected in both ctDNA and tissue (D) Progression-free survival according to mutation clusters in ctDNA (n=85). (E) Progression-free survival according to mutation clusters in tissue (n=100). ctDNA=circulating free tumor-derived DNA. HR=hazard ratio.
Figure S1 from Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Authors: Rosen Ezra Y. , Johnson Melissa L. , Clifford Sarah E. , Somwar Romel , Kherani Jennifer F. , Son Jieun , Bertram Arrien A. , Davare Monika A. , Gladstone Eric , Ivanova Elena V. , Henry Dahlia N. , Kelley Elaine M. , Lin Mika , Milan Marina S.D. , Nair Binoj C. , Olek Elizabeth A. , Scanlon Jenna E. , Vojnic Morana , Ebata Kevin , Hechtman Jaclyn F. , Li Bob T. , Sholl Lynette M. , Taylor Barry S. , Ladanyi Marc , Jänne Pasi A. , Rothenberg S. Michael , Drilon Alexander , Oxnard Geoffrey R.
Published: April 2023

Supplemental Figure 1
Supplementary Data from Characterization and Clinical Outcomes of DNA Mismatch Repair–deficient Small Bowel Adenocarcinoma
Authors: Latham Alicia , Shia Jinru , Patel Zalak , Reidy-Lagunes Diane L. , Segal Neil H. , Yaeger Rona , Ganesh Karuna , Connell Louise , Kemeny Nancy E. , Kelsen David P. , Hechtman Jaclyn F. , Nash Garrett M. , Paty Philip B. , Zehir Ahmet , Tkachuk Kaitlin A. , Sheikh Rania , Markowitz Arnold J. , Mandelker Diana , Offit Kenneth , Berger Michael F. , Cercek Andrea , Garcia-Aguilar Julio , Saltz Leonard B. , Weiser Martin R. , Stadler Zsofia K.
Published: April 2023

Supplemental Table 1: Clinical Characteristics, Treatment, and Recurrence Rates of of Patients with Stage II SBA Supplemental Table 2. Germline variants among SBA patients
Supplementary Table S2 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Authors: Estrada-Bernal Adriana , Le Anh T. , Doak Andrea E. , Tirunagaru Vijaya G. , Silva Shevan , Bull Matthew R. , Smaill Jeff B. , Patterson Adam V. , Kim Chul , Liu Stephen V. , Doebele Robert C.
Published: April 2023

Supplemental table 2. Tarloxotinib-E inhibition of the ErbB family using biochemical kinase assays
Supplementary Figure 1, Supplementary Figure 2, Supplementary Figure 3 from Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors
Authors: Janku Filip , Zhang Halle Huihong , Pezeshki Abdulmohammad , Goel Sanjay , Murthy Ravi , Wang-Gillam Andrea , Shepard Dale R. , Helgason Thorunn , Masters Tyler , Hong David S. , Piha-Paul Sarina A. , Karp Daniel D. , Klang Mark , Huang Steven Y. , Sakamuri Divya , Raina Anjali , Torrisi Jean , Solomon Stephen B. , Weissfeld Alice , Trevino Ernest , DeCrescenzo Gary , Collins Amanda , Miller Maria , Salstrom Jennifer L. , Korn Ronald L. , Zhang Linping , Saha Saurabh , Leontovich Alexey A. , Tung David , Kreider Brent , Varterasian Mary , Khazaie Khashayarsha , Gounder Mrinal M.
Published: April 2023

Supplementary Figure 1. Of 16 patients (7 with and 9 without germination) with available data, 11 (69%) had a decrease in tumor density (-4% to -476%). The most robust decreases in density were observed in patients with germination. Supplementary Figure 2. Tumor antigen specific T-cell responses after C. novyi injection. Supplementary Figure 3. Infiltration in the injected and non-injected tumors.
Supplementary Figure S6 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Authors: Estrada-Bernal Adriana , Le Anh T. , Doak Andrea E. , Tirunagaru Vijaya G. , Silva Shevan , Bull Matthew R. , Smaill Jeff B. , Patterson Adam V. , Kim Chul , Liu Stephen V. , Doebele Robert C.
Published: April 2023

Estimation of human equivalent dose of afatinib in nude mice.
Supplementary Figure S5 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Authors: Estrada-Bernal Adriana , Le Anh T. , Doak Andrea E. , Tirunagaru Vijaya G. , Silva Shevan , Bull Matthew R. , Smaill Jeff B. , Patterson Adam V. , Kim Chul , Liu Stephen V. , Doebele Robert C.
Published: April 2023

Tarloxotinib-E induces apoptosis in EGFR exon 20 insertion mutation, HER2 altered and NRG1 fusion cell lines.
Supplementary Figure S2 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Authors: Estrada-Bernal Adriana , Le Anh T. , Doak Andrea E. , Tirunagaru Vijaya G. , Silva Shevan , Bull Matthew R. , Smaill Jeff B. , Patterson Adam V. , Kim Chul , Liu Stephen V. , Doebele Robert C.
Published: April 2023

Patient derived EGFR exon 20 insertion mutation cell line characterization.
Table S2 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
Authors: Abraham Jim P. , Magee Daniel , Cremolini Chiara , Antoniotti Carlotta , Halbert David D. , Xiu Joanne , Stafford Phillip , Berry Donald A. , Oberley Matthew J. , Shields Anthony F. , Marshall John L. , Salem Mohamed E. , Falcone Alfredo , Grothey Axel , Hall Michael J. , Venook Alan P. , Lenz Heinz-Josef , Helmstetter Anthony , Korn W. Michael , Spetzler David B.
Published: April 2023

Demographics of the cases used in the PDAC RWE testing set.
Figure S2 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
Authors: Abraham Jim P. , Magee Daniel , Cremolini Chiara , Antoniotti Carlotta , Halbert David D. , Xiu Joanne , Stafford Phillip , Berry Donald A. , Oberley Matthew J. , Shields Anthony F. , Marshall John L. , Salem Mohamed E. , Falcone Alfredo , Grothey Axel , Hall Michael J. , Venook Alan P. , Lenz Heinz-Josef , Helmstetter Anthony , Korn W. Michael , Spetzler David B.
Published: April 2023

Cross-validated performance of the training cases. The median TTNT in the Increased Benefit cohort is 3.9 months (52%) longer than the median TTNT in the Decreased Benefit arm (HR = 0.398, 95% CI: 0.244-0.647, log-rank p < 0.001).
Supplementary Data from Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment
Authors: Borowsky Jennifer , Haruki Koichiro , Lau Mai Chan , Dias Costa Andressa , Väyrynen Juha P. , Ugai Tomotaka , Arima Kota , da Silva Annacarolina , Felt Kristen D. , Zhao Melissa , Gurjao Carino , Twombly Tyler S. , Fujiyoshi Kenji , Väyrynen Sara A. , Hamada Tsuyoshi , Mima Kosuke , Bullman Susan , Harrison Tabitha A. , Phipps Amanda I. , Peters Ulrike , Ng Kimmie , Meyerhardt Jeffrey A. , Song Mingyang , Giovannucci Edward L. , Wu Kana , Zhang Xuehong , Freeman Gordon J. , Huttenhower Curtis , Garrett Wendy S. , Chan Andrew T. , Leggett Barbara A. , Whitehall Vicki L.J. , Walker Neal , Brown Ian , Bettington Mark , Nishihara Reiko , Fuchs Charles S. , Lennerz Jochen K. , Giannakis Marios , Nowak Jonathan A. , Ogino Shuji
Published: April 2023

Supplementary Table S1-S4 and Supplementary Figure S1
Figure S2 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
Authors: Salama April K.S. , Palta Manisha , Rushing Christel N. , Selim M. Angelica , Linney Kristen N. , Czito Brian G. , Yoo David S. , Hanks Brent A. , Beasley Georgia M. , Mosca Paul J. , Dumbauld Chelsae , Steadman Katelyn N. , Yi John S. , Weinhold Kent J. , Tyler Douglas S. , Lee Walter T. , Brizel David M.
Published: April 2023

Analyses of additional immune subsets